Adrenal Function Cortisol
Total Page:16
File Type:pdf, Size:1020Kb
Load more
										Recommended publications
									
								- 
												
												United States July 2016 2 Table of Contents
Deuterium Labelled Compounds United States July 2016 2 Table of Contents International Distributors 3 Corporate Overview 4 General Information 5 Pricing and Payment 5 Quotations 5 Custom Synthesis 5 Shipping 5 Quality Control 6 Quotations 6 Custom Synthesis 6 Shipping 6 Quality Control 6 Chemical Abstract Service Numbers 6 Handling Hazardous Compounds 6 Our Products are Not Intended for Use in Humans 7 Limited Warranty 7 Packaging Information 7 Alphabetical Listings 8 Stock Clearance 236 Products by Category 242 n-Alkanes 243 α-Amino Acids, N-Acyl α-Amino Acids, N-t-BOC Protected α-Amino Acid 243 and N-FMOC Protected α-Amino Acids Buffers and Reagents for NMR Studies 245 Detergents 245 Environmental Standards 246 Fatty Acids and Fatty Acid Esters 249 Flavours and Fragrances 250 Gases 253 Medical Research Products 254 Nucleic Acid Bases and Nucleosides 255 Pesticides and Pesticide Metabolites 256 Pharmaceutical Standards 257 Polyaromatic Hydrocarbons (PAHs), Alkyl-PAHs, Amino-PAHs, 260 Hydroxy-PAHs and Nitro-PAHs Polychlorinated Biphenyls (PCBs) 260 Spin Labels 261 Steroids 261 3 International Distributors C Beijng Zhenxiang H EQ Laboratories GmbH Australia K Technology Company Graf-von-Seyssel-Str. 10 Rm. 15A01, Changyin Bld. 86199 Augsburg Austria H No. 88, YongDingLu Rd. Germany Beijing 100039 Tel.: (49) 821 71058246 Belgium J China Fax: (49) 821 71058247 Tel.: (86) 10-58896805 [email protected] China C Fax: (86) 10-58896158 www.eqlabs.de Czech Republic H [email protected] Germany, Austria, China Czech Republic, Greece, Denmark I Hungary, - 
												
												CASODEX (Bicalutamide)
HIGHLIGHTS OF PRESCRIBING INFORMATION • Gynecomastia and breast pain have been reported during treatment with These highlights do not include all the information needed to use CASODEX 150 mg when used as a single agent. (5.3) CASODEX® safely and effectively. See full prescribing information for • CASODEX is used in combination with an LHRH agonist. LHRH CASODEX. agonists have been shown to cause a reduction in glucose tolerance in CASODEX® (bicalutamide) tablet, for oral use males. Consideration should be given to monitoring blood glucose in Initial U.S. Approval: 1995 patients receiving CASODEX in combination with LHRH agonists. (5.4) -------------------------- RECENT MAJOR CHANGES -------------------------- • Monitoring Prostate Specific Antigen (PSA) is recommended. Evaluate Warnings and Precautions (5.2) 10/2017 for clinical progression if PSA increases. (5.5) --------------------------- INDICATIONS AND USAGE -------------------------- ------------------------------ ADVERSE REACTIONS ----------------------------- • CASODEX 50 mg is an androgen receptor inhibitor indicated for use in Adverse reactions that occurred in more than 10% of patients receiving combination therapy with a luteinizing hormone-releasing hormone CASODEX plus an LHRH-A were: hot flashes, pain (including general, back, (LHRH) analog for the treatment of Stage D2 metastatic carcinoma of pelvic and abdominal), asthenia, constipation, infection, nausea, peripheral the prostate. (1) edema, dyspnea, diarrhea, hematuria, nocturia, and anemia. (6.1) • CASODEX 150 mg daily is not approved for use alone or with other treatments. (1) To report SUSPECTED ADVERSE REACTIONS, contact AstraZeneca Pharmaceuticals LP at 1-800-236-9933 or FDA at 1-800-FDA-1088 or ---------------------- DOSAGE AND ADMINISTRATION ---------------------- www.fda.gov/medwatch The recommended dose for CASODEX therapy in combination with an LHRH analog is one 50 mg tablet once daily (morning or evening). - 
												
												An Unexpected Target for Androgen Deprivation Therapy with Prognosis and Diagnostic Implications
Author Manuscript Published OnlineFirst on October 11, 2013; DOI: 10.1158/0008-5472.CAN-13-1462 Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. 1 Androgen glucuronidation: an unexpected target for androgen deprivation therapy with prognosis and diagnostic implications. Laurent Grosse1, Sophie Pâquet1, Patrick Caron1, Ladan Fazli2, Paul S. Rennie2, Alain Bélanger3 and Olivier Barbier1 1Laboratory of Molecular Pharmacology, CHU-Québec Research Centre and Faculty of Pharmacy, Laval University, Québec, Canada 2 Vancouver Prostate Centre at VGH, University of British Columbia, Vancouver, British Columbia, Canada. 3CHU-Québec Research Centre and Faculty of Medicine, Laval University, Québec, Canada Running title: Ablation therapy improves androgen glucuronidation in PCa Keywords: Prostate cancer, androgen ablation therapy, glucuronidation, biomarker, drug target. Financial support: This study was supported by grants from the Canadian Institutes of Health Research (CIHR), the Terry Fox foundation and the Canadian Foundation for Innovation. S. Pâquet is holder of scholarships from CIHR and the Fonds pour la Recherche en Santé du Québec (FRSQ). L. Grosse is supported by a scholarship from the Fonds pour l’Enseignement et la Recherche (FER) from the Faculty of Pharmacy, Laval University (Québec). O. Barbier is holder of salary grants from the CIHR (New Investigator Award #MSH95330) and FRSQ (Junior 2 Scholarship). Address correspondence to: Olivier Barbier, Ph.D. Laboratory of Molecular Pharmacology CHU-Québec Research Centre 2705, boulevard Laurier Québec (QC) G1V 4G2, Canada Phone: 418 654 2296 Fax: 418 654 2769 Email: [email protected] Conflict of interests: Authors have nothing to disclose. Downloaded from cancerres.aacrjournals.org on September 26, 2021. - 
												
												A New Robust Technique for Testing of Glucocorticosteroids in Dogs and Horses Terry E
Iowa State University Capstones, Theses and Retrospective Theses and Dissertations Dissertations 2007 A new robust technique for testing of glucocorticosteroids in dogs and horses Terry E. Webster Iowa State University Follow this and additional works at: https://lib.dr.iastate.edu/rtd Part of the Veterinary Toxicology and Pharmacology Commons Recommended Citation Webster, Terry E., "A new robust technique for testing of glucocorticosteroids in dogs and horses" (2007). Retrospective Theses and Dissertations. 15029. https://lib.dr.iastate.edu/rtd/15029 This Thesis is brought to you for free and open access by the Iowa State University Capstones, Theses and Dissertations at Iowa State University Digital Repository. It has been accepted for inclusion in Retrospective Theses and Dissertations by an authorized administrator of Iowa State University Digital Repository. For more information, please contact [email protected]. A new robust technique for testing of glucocorticosteroids in dogs and horses by Terry E. Webster A thesis submitted to the graduate faculty in partial fulfillment of the requirements for the degree of MASTER OF SCIENCE Major: Toxicology Program o f Study Committee: Walter G. Hyde, Major Professor Steve Ensley Thomas Isenhart Iowa State University Ames, Iowa 2007 Copyright © Terry Edward Webster, 2007. All rights reserved UMI Number: 1446027 Copyright 2007 by Webster, Terry E. All rights reserved. UMI Microform 1446027 Copyright 2007 by ProQuest Information and Learning Company. All rights reserved. This microform edition is protected against unauthorized copying under Title 17, United States Code. ProQuest Information and Learning Company 300 North Zeeb Road P.O. Box 1346 Ann Arbor, MI 48106-1346 ii DEDICATION I want to dedicate this project to my wife, Jackie, and my children, Shauna, Luke and Jake for their patience and understanding without which this project would not have been possible. - 
												
												Conjugated Estrogens Sustained Release Tablets) 0.3 Mg, 0.625 Mg, and 1.25 Mg
PRODUCT MONOGRAPH PrPREMARIN® (conjugated estrogens sustained release tablets) 0.3 mg, 0.625 mg, and 1.25 mg ESTROGENIC HORMONES ® Wyeth Canada Date of Revision: Pfizer Canada Inc., Licensee December 1, 2014 17,300 Trans-Canada Highway Kirkland, Quebec H9J 2M5 Submission Control No: 177429 PREMARIN (conjugated estrogens sustained release tablets) Page 1 of 46 Table of Contents PART I: HEALTH PROFESSIONAL INFORMATION .........................................................3 SUMMARY PRODUCT INFORMATION ...........................................................................3 INDICATIONS AND CLINICAL USE ................................................................................3 CONTRAINDICATIONS ......................................................................................................4 WARNINGS AND PRECAUTIONS ....................................................................................4 ADVERSE REACTIONS ....................................................................................................14 DRUG INTERACTIONS ....................................................................................................20 DOSAGE AND ADMINISTRATION ................................................................................23 OVERDOSAGE ...................................................................................................................25 ACTION AND CLINICAL PHARMACOLOGY ...............................................................25 STORAGE AND STABILITY ............................................................................................28 - 
												
												A Thesis Entitled "APPLICATIONS of GAS CHROMATOGRAPHY
A Thesis entitled "APPLICATIONS OF GAS CHROMATOGRAPHY - MASS SPECTROMETRY IN STEROID CHEMISTRY" Submitted in part fulfilment of the requirements for admittance to the degree of Doctor of Philosophy in The University of Glasgow by T.A. Baillie, B.Sc. University of Glasgow 1973. ProQuest Number: 11017930 All rights reserved INFORMATION TO ALL USERS The quality of this reproduction is dependent upon the quality of the copy submitted. In the unlikely event that the author did not send a com plete manuscript and there are missing pages, these will be noted. Also, if material had to be removed, a note will indicate the deletion. uest ProQuest 11017930 Published by ProQuest LLC(2018). Copyright of the Dissertation is held by the Author. All rights reserved. This work is protected against unauthorized copying under Title 17, United States C ode Microform Edition © ProQuest LLC. ProQuest LLC. 789 East Eisenhower Parkway P.O. Box 1346 Ann Arbor, Ml 48106- 1346 ACKNOWLEDGEMENTS I would like to express my sincere thanks to Dr. C.3.W. Brooks for his guidance and encouragement at all times, and to Professors R.A. Raphael, F.R.S., and G.W. Kirby, for the opportunity to carry out this research. Thanks are also due to my many colleagues for useful discussions, and in particular to Dr. B.S. Middleditch who was associated with me in the work described in Section 3 of this thesis. The work was carried out during the tenure of an S.R.C. Research Studentship, which is gratefully acknowledged. Finally, I would like to thank Miss 3.H. - 
												
												Receptor Af®Nity and Potency of Non-Steroidal Antiandrogens: Translation of Preclinical ®Ndings Into Clinical Activity
Prostate Cancer and Prostatic Diseases (1998) 1, 307±314 ß 1998 Stockton Press All rights reserved 1365±7852/98 $12.00 http://www.stockton-press.co.uk/pcan Review Receptor af®nity and potency of non-steroidal antiandrogens: translation of preclinical ®ndings into clinical activity GJCM Kolvenbag1, BJA Furr2 & GRP Blackledge3 1Medical Affairs, Zeneca Pharmaceuticals, Wilmington, DE, USA; 2Therapeutic Research Department, and 3Medical Research Department, Zeneca Pharmaceuticals, Alderley Park, Maccles®eld, Cheshire, UK The non-steroidal antiandrogens ¯utamide (Eulexin1), nilutamide (Anandron1) and bicalutamide (Casodex1) are widely used in the treatment of advanced prostate cancer, particularly in combination with castration. The naturally occurring ligand 5a-DHT has higher binding af®nity at the androgen receptor than the non-steroidal antiandrogens. Bicalutamide has an af®nity two to four times higher than 2-hydroxy¯utamide, the active metabolite of ¯utamide, and around two times higher than nilutamide for wild-type rat and human prostate androgen receptors. Animal studies have indicated that bicalutamide also exhi- bits greater potency in reducing seminal vesicle and ventral prostate weights and inhibiting prostate tumour growth than ¯utamide. Although preclinical data can give an indication of the likely clinical activity, clinical studies are required to determine effective, well-tolerated dosing regimens. As components of combined androgen blockade (CAB), controlled studies have shown survival bene®ts of ¯utamide plus a luteinising hormone-releasing hormone analogue (LHRH-A) over LHRH-A alone, and for nilutamide plus orchiectomy over orchiectomy alone. Other studies have failed to show such survival bene®ts, including those comparing ¯utamide plus orchiectomy with orchiectomy alone, and nilutamide plus LHRH-A with LHRH-A alone. - 
												
												Pregnancy Increases Norbuprenorphine Clearance in Mice by Induction of Hepatic Glucuronidation
1521-009X/46/2/100–108$25.00 https://doi.org/10.1124/dmd.117.076745 DRUG METABOLISM AND DISPOSITION Drug Metab Dispos 46:100–108, February 2018 Copyright ª 2018 by The American Society for Pharmacology and Experimental Therapeutics Pregnancy Increases Norbuprenorphine Clearance in Mice by Induction of Hepatic Glucuronidation Michael Z. Liao, Chunying Gao, Brian R. Phillips, Naveen K. Neradugomma, Lyrialle W. Han, Deepak Kumar Bhatt, Bhagwat Prasad, Danny D. Shen, and Qingcheng Mao Department of Pharmaceutics, School of Pharmacy, University of Washington, Seattle, Washington Received May 5, 2017; accepted November 17, 2017 ABSTRACT Norbuprenorphine (NBUP) is the major active metabolite of bupre- proteomics quantification revealed that hepatic Ugt1a1 and norphine (BUP) that is commonly used to treat opiate addiction Ugt2b1 protein levels in the same amount of total liver membrane ’ ∼ during pregnancy; it possesses 25% of BUP s analgesic activity proteins were significantly increased by 50% in pregnant mice Downloaded from and 10 times BUP’s respiratory depression effect. To optimize versus nonpregnant mice. After scaling to the whole liver with BUP’s dosing regimen during pregnancy with better efficacy and consideration of the increase in liver protein content and liver safety, it is important to understand how pregnancy affects NBUP weight, we found that the amounts of Ugt1a1, Ugt1a10, Ugt2b1, disposition. In this study, we examined the pharmacokinetics of and Ugt2b35 protein in the whole liver of pregnant mice were NBUP in pregnant and nonpregnant mice by administering the significantly increased ∼2-fold compared with nonpregnant mice. same amount of NBUP through retro-orbital injection. We demon- These data suggest that the increased systemic CL of NBUP in dmd.aspetjournals.org strated that the systemic clearance (CL) of NBUP in pregnant mice pregnant mice is likely caused by an induction of hepatic Ugt increased ∼2.5-fold compared with nonpregnant mice. - 
												
												Drug Metabolism and Pharmacokinetics (DMPK)
Drug Metabolism and Pharmacokinetics (DMPK) Advance Publication by J-STAGE Received; February 25, 2012 Published online; April 27, 2012 Accepted; April 19, 2012 doi; 10.2133/dmpk.DMPK-12-RG-023 Identification and Characterization of Human UDP-Glucuronosyltransferases Responsible for the In Vitro Glucuronidation of Salvianolic acid A De-en Hana,b, Yi Zhengb, Xijing Chenb, Jiake Heb, Di Zhaob, Shuoye Yangb, Chunfeng Zhanga*,Zhonglin Yanga,* aState Key laboratory of Natural Products and Functions, China Pharmaceutical University, Ministry of Education, Nanjing, P. R. China. bCenter of Drug Metabolism and Pharmacokinetics, China Pharmaceutical University, Nanjing, Jiangsu 210009, China. 1 Copyright C 2012 by the Japanese Society for the Study of Xenobiotics (JSSX) Drug Metabolism and Pharmacokinetics (DMPK) Advance Publication by J-STAGE Running title:Glucuronidation of salvianolic acid A in Vitro Corresponding Author: Chunfeng Zhang, PhD State Key laboratory of Natural Products and Functions, China Pharmaceutical University 24# Tong Jia Xiang, Nanjing 210009, PR China. E-mail: [email protected] Phone: +86 25 8337 1694 Zhonglin Yang, PhD State Key laboratory of Natural Products and Functions, China Pharmaceutical University 24# Tong Jia Xiang, Nanjing 210009, PR China. E-mail: [email protected] Phone: +86 25 8337 1694 Fax: +86 25 8337 1694 Number of text pages: 23 Number of tables: 2 Number of figures: 6 2 Drug Metabolism and Pharmacokinetics (DMPK) Advance Publication by J-STAGE ABSTRACT: Glucuronidation is an important pathway in the elimination of salvianolic acid A (Sal A), however the mechanism of UDP-glucuronosyltransferases (UGTs) in this process remains to be investigated. In this study, the kinetics s of salvianolic acid A glucuronidation by pooled human liver microsomes (HLMs), pooled human intestinal microsomes (HIMs) and 12 recombinant UGTs isozymes were investigated. - 
												
												Steroid Metabolites Support Evidence of Autism As a Spectrum
behavioral sciences Article Steroid Metabolites Support Evidence of Autism as a Spectrum Benedikt Andreas Gasser 1,*, Johann Kurz 2, Bernhard Dick 1,3 and Markus Georg Mohaupt 1,4 1 Department of Clinical Research, University of Bern, 3010 Berne, Switzerland; [email protected] (B.D.); [email protected] (M.G.M.) 2 Intersci Research Association, Karl Morre Gasse 10, 8430 Leibnitz, Austria; [email protected] 3 Division of Nephrology/Hypertension, University of Bern, 3010 Berne, Switzerland 4 Teaching Hospital Internal Medicine, Lindenhofgruppe, 3006 Berne, Switzerland * Correspondence: [email protected] Received: 30 March 2019; Accepted: 6 May 2019; Published: 9 May 2019 Abstract: Objectives: It is common nowadays to refer to autism as a spectrum. Increased evidence of the involvement of steroid metabolites has been shown by the presence of stronger alterations in Kanner’s syndrome compared with Asperger syndrome. Methods: 24 h urine samples were collected from 20 boys with Asperger syndrome, 21 boys with Kanner’s syndrome, and identically sized control groups, each matched for age, weight, and height for comprehensive steroid hormone metabolite analysis via gas chromatography–mass spectrometry. Results: Higher levels of most steroid metabolites were detected in boys with Kanner’s syndrome and Asperger syndrome compared to their matched controls. These differences were more pronounced in affected individuals with Kanner’s syndrome versus Asperger syndrome. Furthermore, a specific and unique pattern of alteration of androsterone, etiocholanolone, progesterone, tetrahydrocortisone, and tetrahydrocortisol was identified in boys with Kanner’s syndrome and Asperger syndrome. Interestingly, in both matched samples, only androsterone, etiocholanolone, progesterone, tetrahydrocortisone, tetrahydrocortisol, and 5a-tetrahydrocortisol groups were positively correlated. - 
												
												Section 2.6.4 Pharmacokinetics Written Summary EMTRICITABINE
SECTION 2.6 NONCLINICAL SUMMARY Section 2.6.4 Pharmacokinetics Written Summary EMTRICITABINE/ RILPIVIRINE/ TENOFOVIR DISOPROXIL FUMARATE FIXED-DOSE COMBINATION 17 August 2010 CONFIDENTIAL AND PROPRIETARY INFORMATION Emtricitabine/Rilpivirine/Tenofovir Disoproxil Fumarate Section 2.6.4 Pharmacokinetics Written Summary Final TABLE OF CONTENTS SECTION 2.6 NONCLINICAL SUMMARY........................................................................................................1 TABLE OF CONTENTS .......................................................................................................................................2 GLOSSARY OF ABBREVIATIONS AND DEFINITION OF TERMS ..............................................................5 2.6. NONCLINICAL SUMMARY.......................................................................................................................8 2.6.4. PHARMACOKINETICS WRITTEN SUMMARY .........................................................................8 2.6.4.1. Brief Summary................................................................................................................8 2.6.4.2. Methods of Analysis .....................................................................................................14 2.6.4.2.1. Emtricitabine............................................................................................14 2.6.4.2.2. Rilpivirine ................................................................................................14 2.6.4.2.3. Tenofovir Disoproxil Fumarate - 
												
												Mass Spec Testing for Steroid Hormone Profiles: Making an Impact on Patient Care
Mass Spec Testing for Steroid Hormone Profiles: Making an Impact on Patient Care R.J. Singh, Ph.D. Mayo Clinic Objectives •Congenital Adrenal Hyperplasia (CAH) •Sex Steroids •Cushing’s CAH New Born Screening 1 CAH CholesterolBiosynthesis of Steroids Pregnenolone 17- OH Pregnenolone DHEA ase ’ -----------------------------------------------------------------------------3SDH 17,20 desmolase 17 OH Progesterone 17-OH Progesterone Androstenedione 21 OH'ase 17b SDH ---------------------------------------------- Aromatase 21-Deoxycorti- 11-deoxycortisol Testosterone costerone 11 OH'ase Aromatase ---------------------------------------------- Estrone Corticosterone Cortisol Estradiol 17b SDH 18 OH'ase ---------------------- Cortisone --- Aldosterone STEROID PROFILE BY LC MS/MS TIC: from 051200-36 9.5e5 8 9.0e5 1. Cortisone 8.5e5 2. Cortisol, Cortisol d-4 8.0e5 3. 21-Deoxycortisol 4. Corticosterone 7.5e5 5. 11-Deoxycortisol 7.0e5 6. Androstendione 6.5e5 7. DOC 8. 17-Hydroxyprogesterone 6.0e5 17-Hydroxypregnenolone 5.5e5 9. Progesterone 5.0e5 10. Pregnenolone Intensity, cps 4.5e5 4.0e5 3.5e5 3.0e5 6 2.5e5 5 7 10 2.0e5 1.5e5 34 2 1.0e5 1 5.0e4 9 1.0 2.0 3.0 4.0 5.0 6.0 7.0 8.0 9.0 Time, min 6 2 Basics of MS Method Basics of MS Method Lack of Standardization 3 RIA vs. LC-MS/MS 14000 12000 10000 8000 6000 4000 Mayo LC/MS/MS ng/dL LC/MS/MS Mayo 2000 0 0 2000 4000 6000 8000 10000 12000 14000 Ext/RIA ng/dL Correlation Between Two Sites 4 Bland Altman Plot (N=76) 1000 + 2 SD = 801.4 500 + 1 SD = 405.8 Mean difference= 10.1 0 (ng/dL) - 1 SD = 385.6 -500